Jinzanghuang Tibet (OTC BB:JZHG)

Leling Jinzanghuang Biotech Co., Ltd, a Tibetan health products company,  goes public via a reverse merger transaction on January 12, 2009.  Upon completion of the Share Exchange, there were 40,644,780 shares common stock issued and outstanding. 

The company has yet to generate any significant revenues, as the market for Tibetan pharmaceuticals in China is only a very small portion of the overall medical market in China. The annual production of Tibetan medicine amounts to approximately 1500 tons with more than 293 items marketed.  However, the growth rate of the market for Tibetan pharmaceuticals is substantial. One factor spurring growth has been the willingness of Chinese regulators to accredit products based on Tibetan medicine. At the present time, this accreditation includes:

• 14 products that have been listed on the Protected Chinese Traditional Medicine List;
• 24 products that have been included in the National Medicine Index;
• 218 products that have been certified by the SFDA; and
• 20+ products that have registered trademarks in China.

Source: SEC Form 8K (January 12, 2009)